Literature DB >> 21923651

ASXL1 mutations in primary and secondary myelofibrosis.

Clara Ricci, Orietta Spinelli, Silvia Salmoiraghi, Guido Finazzi, Alessandra Carobbio, Alessandro Rambaldi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21923651     DOI： 10.1111/j.1365-2141.2011.08865.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

2.  Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Ipek Yonal-Hindilerden; Aynur Daglar-Aday; Basak Akadam-Teker; Ceylan Yilmaz; Meliha Nalcaci; Akif Selim Yavuz; Deniz Sargin
Journal:  J Blood Med       Date:  2015-06-01

3.  Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.

Authors:  Francisca Ferrer-Marín; Beatriz Bellosillo; Luz Martínez-Avilés; Gloria Soler; Pablo Carbonell; Ginés Luengo-Gil; Eva Caparrós; José M Torregrosa; Carlos Besses; Vicente Vicente
Journal:  J Hematol Oncol       Date:  2013-09-08       Impact factor: 17.388

4.  Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.

Authors:  Helene Myrtue Nielsen; Christen Lykkegaard Andersen; Maj Westman; Lasse Sommer Kristensen; Fazila Asmar; Torben Arvid Kruse; Mads Thomassen; Thomas Stauffer Larsen; Vibe Skov; Lise Lotte Hansen; Ole Weis Bjerrum; Hans Carl Hasselbalch; Vasu Punj; Kirsten Grønbæk
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

5.  JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Valentina Poletto; Margherita Massa; Rita Campanelli; Laura Villani; Elisa Bonetti; Gianluca Viarengo; Paolo Catarsi; Catherine Klersy; Vittorio Rosti
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

6.  Molecular genetics of myelofibrosis and its associated disease phenotypes.

Authors:  Ali Tabarroki; Ramon V Tiu
Journal:  Transl Med UniSa       Date:  2014-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.